Gilead Sciences, Inc. (ETR:GIS)

Germany flag Germany · Delayed Price · Currency is EUR
92.20
0.00 (0.00%)
Jun 25, 2025, 9:27 AM CET
41.15%
Market Cap 114.45B
Revenue (ttm) 26.59B
Net Income (ttm) 5.52B
Shares Out n/a
EPS (ttm) 4.38
PE Ratio 20.74
Forward PE 12.99
Dividend 2.84 (3.08%)
Ex-Dividend Date Jun 13, 2025
Volume 3
Average Volume 749
Open 92.58
Previous Close 92.20
Day's Range 92.20 - 92.58
52-Week Range 61.00 - 111.84
Beta 0.31
RSI 40.90
Earnings Date Aug 1, 2025

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Sector Healthcare
Founded 1987
Employees 17,600
Stock Exchange Deutsche Börse Xetra
Ticker Symbol GIS
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD Financial Statements

News

Gilead Sciences - Born With HIV in the 80s: Kim's Story of Growing Up as a Dandelion

NORTHAMPTON, MA / ACCESS Newswire / June 24, 2025 / Kim Canady was only nine years old in 1996 when she faced the unimaginable loss of losing both her parents in the same year. At the time, she didn't...

20 hours ago - Wallstreet:Online

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD).  Such investors are advis...

1 day ago - GlobeNewsWire

Gilead Sciences CEO Daniel O'Day on HIV prevention injection approval

Gilead Sciences CEO Daniel O'Day explains why he believes the biopharma's HIV prevention injection Yeztugo, which received approval from the Food and Drug Administration last week, is a "milestone mom...

1 day ago - CNBC Television

Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV

Gilead Sciences chairman and CEO Daniel O'Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention medication, how the twice-yearly antiviral drug Yeztugo works, the importan...

1 day ago - CNBC Television

Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV

Gilead Sciences chairman and CEO Daniel ODay joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention medication, how the twice-yearly antiviral drug Yeztugo works, the importanc...

1 day ago - CNBC

Watch CNBC's full interview with Gilead Sciences chairman and CEO Daniel ODay

Gilead Sciences chairman and CEO Daniel ODay joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention medication, how the twice-yearly antiviral drug Yeztugo works, the importanc...

1 day ago - CNBC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised to...

2 days ago - PRNewsWire

FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag

During market trading hours on Wednesday, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.’s (NASDAQ: GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduc...

4 days ago - Benzinga

FDA approves first twice-yearly injection that prevents HIV infection

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.

5 days ago - Fox News

U.S. approves twice-a-year shot to prevent HIV but cuts to public health and foreign aid cloud its prospects

The shot made by Gilead Sciences nearly eliminated new infections in two groundbreaking studies of people at high risk, better than daily preventive pills they can forget to take.

5 days ago - Fortune

AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention

LOS ANGELES--(BUSINESS WIRE)--AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention.

6 days ago - Business Wire

Twice-a-year shot to prevent HIV approved in U.S.

The U.S. has approved the world's only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday.

6 days ago - CBC News

FDA approves 6-month HIV prevention shot

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more than...

6 days ago - The Hill

Gilead Sciences Wins Approval For Highly Effective HIV Prevention Drug

Gilead Sciences won Food and Drug Administration approval Wednesday for a highly effective drug to prevent HIV infection.

6 days ago - Investor's Business Daily

Yeztugo (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure...

6 days ago - Wallstreet:Online

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company's injectable...

6 days ago - Business Wire

FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option

The launch of the injection faces potential threats, including the Trump administration's proposed cuts to federal funding for HIV prevention efforts.

6 days ago - CNBC

US FDA approves Gilead's twice-yearly injection for HIV prevention

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.

6 days ago - Reuters

FDA approves powerful HIV drug with the potential to end the epidemic in the U.S.

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday.

6 days ago - NBC News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are advised...

6 days ago - GlobeNewsWire

Should You Buy Gilead Stock At $110?

Despite a recent setback with an FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performa...

6 days ago - Forbes

Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report

Gilead Sciences Inc (NASDAQ: GILD) is facing mounting pressure to price its long-acting HIV prevention drug, lenacapavir, affordably as it prepares for U.S. regulatory approval on June 19. In Decembe...

7 days ago - Benzinga

GILD ALERT: Ongoing Investigation Into Gilead Sciences, Inc. - Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / June 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Gilead Sciences, Inc. ("Gilead Sciences, Inc.") (NASDAQ:GILD) concerning ...

7 days ago - Accesswire

Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

7 days ago - Accesswire